{"id":653385,"date":"2023-05-29T09:20:01","date_gmt":"2023-05-29T09:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=653385"},"modified":"2023-05-29T09:20:01","modified_gmt":"2023-05-29T09:20:01","slug":"angioimmunoblastic-tcell-lymphoma-market-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-states-delveinsight-key-companiestakeda-amgen-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/angioimmunoblastic-tcell-lymphoma-market-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-states-delveinsight-key-companiestakeda-amgen-pharmaceuticals_653385.html","title":{"rendered":"Angioimmunoblastic T-cell Lymphoma Market Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Key Companies-Takeda, Amgen Pharmaceuticals"},"content":{"rendered":"
\n
\"Angioimmunoblastic<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032<\/a>“<\/strong> report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, epidemiology insights, Angioimmunoblastic T-Cell Lymphoma market trends, therapies, and key companies working in the Angioimmunoblastic T-Cell Lymphoma Market in the 7MM.<\/p>\n

Angioimmunoblastic T-cell Lymphoma Overview<\/strong><\/p>\n

Angioimmunoblastic T-cell lymphoma (AITL) is a rare, often but not always, an aggressive (fast-growing) form of peripheral T-cell lymphoma (PTCL). While AITL only accounts for one to two percent of all NHL cases in the United States, it is one of the more common subtypes of T-cell lymphomas<\/p>\n

The typical patient with angioimmunoblastic T-cell lymphoma (AITL) is either middle-aged or elderly, and no gender preference for this disease has been observed. AITL comprises 15–20% of peripheral T-cell lymphomas and 1–2% of all non-Hodgkin lymphomas.<\/p>\n

\"\"<\/p>\n

Learn more about the Angioimmunoblastic T-cell Lymphoma market @ Angioimmunoblastic T-cell Lymphoma Market Landscape<\/a><\/strong><\/p>\n

 Angioimmunoblastic T-cell Lymphoma Epidemiological Segmentation <\/strong><\/p>\n